26
|
Kikuchi-Taura A, Yura A, Tsuji S, Ohshima S, Kitatoube A, Shimizu T, Nii T, Katayama M, Teshigawara S, Yoshimura M, Kudo-Tanaka E, Harada Y, Matsushita M, Hashimoto J, Saeki Y. Monocyte CD64 expression as a novel biomarker for the disease activity of systemic lupus erythematosus. Lupus 2015; 24:1076-80. [DOI: 10.1177/0961203315579093] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Accepted: 03/02/2015] [Indexed: 12/19/2022]
Abstract
Objective Interferon alpha (IFN-α) is a key cytokine associated with systemic lupus erythematosus (SLE). IFN-α induces the expression of CD64 on monocytes (mCD64). Although enhanced mCD64 expression has been reported in patients with SLE, it has never been assessed quantitatively. The aim of this study was to investigate whether or not mCD64 expression correlates with SLE disease activity. Methods The mCD64 expression levels were assessed quantitatively in 40 patients with active or inactive SLE by using flow cytometry. The mCD64 expression levels were subsequently compared with the SLE disease activity index (SLEDAI) and levels of existing SLE activity biomarkers, such as anti-DNA antibody, complements, and so on. Results The mCD64 expression was significantly higher in active disease than in inactive disease SLE (median molecules/cell, interquartile range: 34,648, 8174–24,932 and 20,865, 6357–21,503, respectively; p < 0.001). The levels of mCD64 expression strongly correlated with SLEDAI ( r = 0.68, p < 0.001). Conclusion The mCD64 expression is a simple and useful biomarker for evaluating disease activity in patients with SLE.
Collapse
|
27
|
Sasaki H, Hirose Y, Yazaki T, Kimura T, Fujiwara H, Kitamura Y, Katayama M, Toda M, Ohira T, Yoshida K. MOLECULAR-GUIDED NEOADJUVANT APPROACH FOR CHEMOSENSITIVE GLIOMAS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou209.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Tsuji S, Yura A, Katayama M, Watanabe A, Teshigawara S, Yoshimura M, Tanaka E, Harada Y, Kagawa K, Katada Y, Matsushita M, Ohshima S, Hashimoto J, Saeki Y. AB0449 Baseline Procalcitonin (PCT) Level as A Predictive Marker for Clinical Remission (DAS28-ESR, CDAI) at 52 Weeks in Biologic NaÏVe Rheumatoid Arthritis (RA) Patients Treated by TOCILIZUMAB (TCZ); A Single Center Retrospective Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2437] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
29
|
Kikuchi-Taura A, Tsuji S, Ohshima S, Yura A, Katayama M, Watanabe A, Teshigawara S, Yoshimura M, Kudo-Tanaka E, Harada Y, Katada Y, Matsushita M, Kitatoube A, Hashimoto J, Saeki Y. AB0943 Monocyte/Neutrophil (M/N) CD64 Ratio is Useful for Differentiating Infection from Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
30
|
Kikuchi-Taura A, Tsuji S, Ohshima S, Yura A, Katayama M, Watanabe A, Teshigawara S, Yoshimura M, Kudo-Tanaka E, Harada Y, Katada Y, Matsushita M, Kitatoube A, Hashimoto J, Saeki Y. SAT0002 Quantitative CD64 Molecules on Peripheral Blood Monocytes in Systemic Lupus Erythematosus (SLE). Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Tanaka E, Katayama M, Satoru T, Yoshimura M, Watanabe A, Tsuji S, Tsuboi H, Hirao M, Yura A, Harada Y, Katada Y, Matsushita M, Hashimoto J, Oshima S, Saeki Y. THU0249 Early Therapeutic Intervention with Methotrexate (MTX) Prevents Development of Rheumatoid Arthritis (RA) in Patients with Undifferentiated Arthritis (UA), Even in the Presence of Smoking or the HLA-DR B1-Shared Epitope. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Teshigawara S, Tsuji S, Kikuchi-Taura A, Yura A, Katayama M, Watanabe A, Yoshimura M, Kudo-Tanaka E, Harada Y, Katada Y, Matsushita M, Ohshima S, Hashimoto J, Saeki Y. FRI0091 Neutrophil CD64 (NCD64) as A Useful Marker for Differentiating Organizing Pneumonia (OP) from Bacterial Pneumonia (BP) in Rheumatoid Arthritis (RA):. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
33
|
Ishikawa H, Kaneko A, Hattori Y, Kida D, Katayama M, Sato T, Osawa Y. AB0246 Study of the Antibody Titer by Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents -Examination of Multiple Dose-. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
Katada Y, Harada Y, Yura A, Yoshimura M, Katayama M, Teshigawara S, Tanaka E, Watanabe A, Oshima S, Tsuji S, Saeki Y, Murata J, Nakanishi F, Masuda E, Hijioka T, Yamaguchi N, Hashimoto J, Matsushita M. AB0940 The Prevalence of Achalasia among Patients with Autoimmune Diseases. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
35
|
Katayama M, Tsuji S, Kikuchi-Taura A, Kitatobe A, Yura A, Teshigawara S, Yoshimura M, Watanabe A, Kudo-Tanaka E, Harada Y, Matsushita M, Katada Y, Oshima S, Hashimoto J, Saeki Y. FRI0079 Plasma Pentraxin3 (PTX3) as A Novel Useful Biomarker for Infection in Patients with Rheumatoid Arthritis (RA). Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Yura A, Tsuji S, Kitatoube A, Kikuchi-Taura A, Katayama M, Watanabe A, Teshigawara S, Yoshimura M, Kudo-Tanaka E, Harada Y, Matsushita M, Katada Y, Ohshima S, Hashimoto J, Saeki Y. SAT0003 Quantitative Monocyte CD64 (MCD64) Expression is Useful Biomarker for Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Saeki Y, Matsui T, Kagawa K, Ohshima S, Matsushita M, Tanaka-Kudo E, Tsuji SI, Yoshimura M, Watanabe A, Teshigawara S, Katayama M, Katada Y, Harada Y, Yura A, Hashimoto J, Tohma S. SAT0074 Smoking Cessation Significantly Reduces Failure of BIOLOGICS (BIO)-Treatment in Rheumatoid Arthritis (RA): from the “Ninja” Registry Cohort of Japanese Patients:. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
38
|
Uemura T, Matsumoto T, Miyake K, Uno M, Ohnishi S, Kato T, Katayama M, Shinamura S, Hamada M, Kang MJ, Takimiya K, Mitsui C, Okamoto T, Takeya J. Split-gate organic field-effect transistors for high-speed operation. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2014; 26:2983-2988. [PMID: 24464678 DOI: 10.1002/adma.201304976] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2013] [Revised: 12/13/2013] [Indexed: 06/03/2023]
Abstract
Split-gate organic field-effect transistors have been developed for high-speed operation. Owing to the combination of reduced contact resistance and minimized parasitic capacitance, the devices have fast switching characteristics. The cutoff frequencies for the vacuum-evaporated devices and the solution-processed devices are 20 and 10 MHz, respectively. A speed of 10 MHz is the fastest device reported so far among solution-processed organic transistors.
Collapse
|
39
|
Maeda Y, Matsushita M, Yura A, Teshigawara S, Katayama M, Yoshimura M, Watanabe A, Tanaka E, Tsuji S, Kitatobe A, Harada Y, Ohshima S, Katada Y, Hashimoto J, Ogata K, Takahashi T, Tsuji H, Nomoto K, Kumanogoh A, Takeda K, Saeki Y. OP0191 The Fecal Microbiota of Rheumatoid Arthritis Patients Differs from that of Healthy Volunteers and is Considerably Altered by Treatment with Biologics. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.396] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Terao C, Ohmura K, Ikari K, Kochi Y, Maruya E, Katayama M, Shimada K, Murasawa A, Honjo S, Takasugi K, Matsuo K, Tajima K, Suzuki A, Yamamoto K, Momohara S, Yamanaka H, Yamada R, Saji H, Matsuda F, Mimori T. SAT0002 ACPA-negative rheumatoid arthritis consists of two genetically distinct subsets based on RF positivity. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Yoshimura M, Maeda Y, Katayama M, Watanabe A, Tanaka E, Tsuji S, Harada Y, Katada Y, Matsushita M, Hashimoto J, Ohshima S, Saeki Y. SAT0103 The analysis of reasons of discontinuing biologics in japanese patients with rheumatoid arthritis; from the ninja (national database of rheumatic disease by IR-net in japan). Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.3050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
42
|
Tsuji S, Yura A, Katayama M, Watanabe A, Teshigawara S, Yoshimura M, Tanaka E, Harada Y, Katada Y, Matsushita M, Ohshima S, Hashimoto J, Saeki Y. SAT0135 Procalcitonin (PCT) Level as a Predictor Of Remission in Rheumatoid Arthritis (RA) Patients Receiving Tocilizumab (TCZ): A Single-Center Retrospective Study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Matsushita M, Kobayashi T, Okada M, Mori Y, Yoshimura M, Teshigawara S, Katayama M, Watanabe A, Tanaka E, Tsuji S, Kitatobe A, Yura A, Harada Y, Katada Y, Ohshima S, Hashimoto J, Minamino Y, Kakudo K, Yoshie H, Saeki Y. SAT0059 Association of Serum Antibody Responses to Porphyromonas Gingivalis and Periodontal Conditions with Clinical Response to Biologics in Rheumatoid Arthritis Patients. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Saeki Y, Ohshima S, Matsushita M, Tanaka-Kudo E, Tsuji S, Yoshimura M, Watanabe A, Katayama M, Teshigawara S, Katada Y, Harada Y, Yura A, Kagawa K, Hashimoto J, Tohma S. SAT0144 The Causes of Discontinuation of Biologics(Bio)-Use in the Treatment of Rheumatoid Arthritis (RA) Under Practical Circumstances in Japan: from the “Ninja” Registry. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Tsuji S, Ohshima S, Yura A, Katayama M, Watanabe A, Teshigawara S, Yoshimura M, Tanaka E, Harada Y, Katada Y, Matsushita M, Taura A, Kitatoube A, Takahashi G, Endo S, Hashimoto J, Saeki Y. THU0442 Serum Prepsepsin (Soluble CD14-Subtype) as a Novel Useful Biomaker for Infection in Patients with Rheumatoid Arthritis (RA). Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
46
|
Maeda Y, Matsushita M, Katayama M, Yoshimura M, Watanabe A, Tanaka E, Tsuji S, Kitatobe A, Harada Y, Ohshima S, Katada Y, Hashimoto J, Saeki Y, Takahashi T, Tsuji H, Nomoto K, Takeda K. SAT0079 The analysis of fecal microbiota in rheumatoid arthritis patients compared to healthy volunteers using bacterial RRNA-targeted reverse transcription-quantitative PCR. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.3026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
47
|
Ishikawa H, Kanda H, Kida D, Kaneko A, Katayama M, Sato T. FRI0237 Study of the antibody titer by influenza vaccination in rheumatoid arthritis patients treated with biological agents. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Ohshima S, Nakagawa T, Taguchi A, Taguchi T, Kitatobe A, Kudo-Tanaka E, Tsuji S, Maeda Y, Yoshimura M, Watanabe A, Katayama M, Harada Y, Katada Y, Hashimoto J, Matsushita M, Kondo A, Saeki Y. SAT0415 Diagnostic and predictive value of novel method for analyzing IGG galactosylation in rheumatoid arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.3361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Katayama M, Jiamsripong P, Bukatina AE, Lombari TR, Mcmahon EM, Gades NM, Belohlavek M. Optimized administration regimen of lopinavir for a myocardial ischaemia reperfusion study in Sprague–Dawley rats. Lab Anim 2013; 47:122-6. [DOI: 10.1177/0023677213476864] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Pharmacokinetics of drugs may differ between small and large mammals (including humans); therefore, drug testing in animal models must be carefully designed. Sprague–Dawley rats were used in cardiac experiments, during which the lopinavir concentration in serum had to match human therapeutic levels (4–10 μg/mL). Lopinavir was administered as a co-formulated drug of lopinavir and ritonavir. It was found that after a single administration of a standard human peroral dose (lopinavir 13.3 mg/kg of body weight), the serum concentration of lopinavir was only one-tenth of the target level. It remained below the minimum target level even after 10-fold the standard dose was administered. After initial pilot tests, a dose escalation study was conducted with oral doses 10- and 15-fold the standard clinical dose of lopinavir (i.e. 133 and 200 mg/kg, respectively). A second administration 2 h later effectively increased and maintained higher concentrations during the experimental ischaemia and reperfusion periods. A dose-dependent increase in serum concentration of the drug was observed. Thus, the target therapeutic serum level of lopinavir in the rats was achieved by administrating 10- to 15-fold the standard human dose twice, separated by a 2 h interval.
Collapse
|
50
|
Habara H, Mishima Y, Nakanii N, Honda S, Katayama M, Gremillet L, Willingale L, Maksimchuk A, Krushelnick K, Tanaka K. Enhanced energy coupling by using structured nano-wire targets. EPJ WEB OF CONFERENCES 2013. [DOI: 10.1051/epjconf/20135917007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|